Q2 FY2026 EarningsQ2 FY2026 results outperformed consensus across key financial metrics, driven by the strong commercial uptake of Emrosi. Total revenue of $18.5M beat the $18.4M expectation, while the GAAP net loss of $0.3M was significantly narrower than the $0.6M loss projected by analysts. GAAP EPS of -$0.01 comfortably beat the -$0.02 consensus. The core driver was Emrosi, which contributed $8.1M to revenue (up 189% YoY), offsetting declines in legacy products and Qbrexza due to coverage mix and generic competition.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Journey Medical(DERM) the Revenue is 18.51 M (+23.33%), Beat estimate;the EBIT is 456 K (+115.9%), Beat estimate;the EPS is -0.01 (+93.75%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.02B23.33%
0.02B22.37%
+0.00B0.96%
EBITExceed expectations
0.00B115.86%
0.00B114.07%
+0.00B1.79%
EPSExceed expectations
-0.0193.75%
-0.022585.94%
+0.01257.81%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf